1-(3-溴丙氧基)-4-硝基苯 | 13094-50-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-溴丙氧基)-4-硝基苯
• 中文别名: 1-(3-苯氧基溴)-4-硝基苯；1-(Gamma-溴丙氧基)-4-硝基苯；1-(3-丙氧基溴)-4-硝基苯
• 英文名称: 1-(3-bromopropoxy)-4-nitrobenzene
• CAS: 13094-50-3
• 化学式: C₉H₁₀BrNO₃
• mdl: MFCD00596643
• 分子量: 260.087
• InChiKey: LIBYGKUWXRBMPA-UHFFFAOYSA-N

物化性质

• 熔点：
  56-58 °C
• 沸点：
  175-177 °C(Press: 2 Torr)
• 密度：
  1.6737 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn,Xi
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2909309090
• 储存条件：
  存放于阴凉干燥处。

SDS

Name:	1-(5-Bromopropoxy)-4-nitrobenzene 97% Material Safety Data Sheet
Synonym:
CAS:	13094-50-3

Section 1 - Chemical Product MSDS Name:1-(5-Bromopropoxy)-4-nitrobenzene 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
13094-50-3	1-(5-Bromopropoxy)-4-nitrobenzene	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. Lachrymator (substance which increases the flow of tears).
Skin:
Causes skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 13094-50-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 56 - 58 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: NO2C6H4O(CH2)3Br
Molecular Weight: 260.09

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 13094-50-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(5-Bromopropoxy)-4-nitrobenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 13094-50-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 13094-50-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 13094-50-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-溴丙氧基)-4-硝基苯 在 4-二甲氨基吡啶 、 氯化铵 、 锌 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 4-(3-吗啉-4-基-丙氧基)-苯胺
  参考文献：
  名称：

  4′-Alkoxyl substitution enhancing the anti-mitotic effect of 5-(3′,4′,5′-substituted)anilino-4-hydroxy-8-nitroquinazolines as a novel class of anti-microtubule agents

  摘要：

  Mitosis inhibitors are powerful anticancer drugs. Based on a novel anti-microtubule agent of 5-(4'-methoxy)anilino-4-hydroxy-8-nitroquinazoline, a series of 5-(3',4',5'-substituted)anilino-4-hydroxy-8- nitroquinazolines were designed and synthesized to investigate the effect of the substitution on the inhibitory activity against mitotic progression of tumor cells. The large alkoxyl substitution on the 4'-position of 5-anilino ring is beneficial for the potency. The 5-(3',4,5'-trimethoxy)anilino-8-nitroquinazoline (1h) displays an overwhelming activity in arresting the cells at the G2/M phase, providing a promising new template for further development of potent microtubule-targeted anti-mitotic drugs. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.058
• 作为产物：
  描述：

  对硝基苯酚 在 N-溴代丁二酰亚胺(NBS) 、 sodium carbonate 、 三苯基膦 、 potassium iodide 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 1-(3-溴丙氧基)-4-硝基苯
  参考文献：
  名称：

  4′-Alkoxyl substitution enhancing the anti-mitotic effect of 5-(3′,4′,5′-substituted)anilino-4-hydroxy-8-nitroquinazolines as a novel class of anti-microtubule agents

  摘要：

  Mitosis inhibitors are powerful anticancer drugs. Based on a novel anti-microtubule agent of 5-(4'-methoxy)anilino-4-hydroxy-8-nitroquinazoline, a series of 5-(3',4',5'-substituted)anilino-4-hydroxy-8- nitroquinazolines were designed and synthesized to investigate the effect of the substitution on the inhibitory activity against mitotic progression of tumor cells. The large alkoxyl substitution on the 4'-position of 5-anilino ring is beneficial for the potency. The 5-(3',4,5'-trimethoxy)anilino-8-nitroquinazoline (1h) displays an overwhelming activity in arresting the cells at the G2/M phase, providing a promising new template for further development of potent microtubule-targeted anti-mitotic drugs. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.058

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
  申请人：AstraZeneca AB

  公开号：US06593326B1

  公开（公告）日：2003-07-15

  A pyrimidine derivative of formula (I): wherein: R1 is an optional substituent as defined within; Rx is selected from halo, hydroxy, nitro, amino, cyano, mercapto, carboxy, sulphamoyl, formamido, ureido or carbamoyl or a group of formula (Ib): A—B—C— as defined within; Q1 and Q2 are independently selected from aryl, a 5- or 6-membered monocyclic moiety; and a 9- or 10-membered bicyclic heterocyclic moiety; and one or both of Q1 and Q2 bears on any available carbon atom one substituent of formula (Ia) as defined within; and Q1 and Q2 are optionally further substituted; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof; are useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  式（I）的嘧啶衍生物： 其中：R1是如定义的可选取代基；Rx选自卤素、羟基、硝基、氨基、氰基、巯基、羧基、磺胺基、甲酰胺基、脲基或氨基甲酰基或如定义的式（Ib）的基团：A—B—C—；Q1和Q2独立选自芳基、5-或6-成员单环基；和9-或10-成员双环杂环基；Q1和Q2中的一个或两个在任一可用碳原子上带有如定义的式（Ia）的取代基；Q1和Q2可进一步取代；或其药学上可接受的盐或体内水解酯；可用作抗癌剂；并描述了其制备方法和含有它们的药物组合物。
• COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
  申请人：XW LABORATORIES INC.

  公开号：US20200102289A1

  公开（公告）日：2020-04-02

  The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.

  本发明涉及作为H3R拮抗剂的化合物(A)的公式，以及它们的制备和用途，并进一步涉及包含这些化合物的药物组合物及其用途作为组胺3受体（H3R）功能调节剂。本发明还涉及这些化合物或药物组合物在治疗或预防与人类H3R功能相关的某些疾病和疾病中的用途。
• Room Temperature, Metal-Free Arylation of Aliphatic Alcohols
  作者：Raju Ghosh、Erik Lindstedt、Nazli Jalalian、Berit Olofsson

  DOI：10.1002/open.201402006

  日期：2014.4

  are demonstrated as efficient arylating agents of aliphatic alcohols under metal‐free conditions. The reaction proceeds at room temperature within 90 min to give alkyl aryl ethers in good to excellent yields. Aryl groups with electron‐withdrawing substituents are transferred most efficiently, and unsymmetric iodonium salts give chemoselective arylations. The methodology has been applied to the formal

  在无金属条件下，二芳基碘盐被证明是脂肪醇的有效芳基化剂。反应在室温下在 90 分钟内进行，以良好至极好的收率得到烷基芳基醚。具有吸电子取代基的芳基转移最有效，不对称碘盐会产生化学选择性芳基化。该方法已应用于丁氧卡因的正式合成。
• Discovery of Diphenoxy Derivatives with Flexible Linkers as Ligands for β-Amyloid Plaques
  作者：Jianhua Jia、Longfei Zhang、Jia Song、Jiapei Dai、Mengchao Cui

  DOI：10.1021/acs.molpharmaceut.0c00537

  日期：2020.11.2

  analysis revealed that modification on the linkers or substituents tolerated great flexibility, which challenged the long-held belief that rigid and planar structures are exclusively favored for Aβ binding. Three ligands were labeled by iodine-125, and they exhibited good properties in vitro and in vivo, which further supported that this flexible scaffold was potential and promising for the development

  具有 π 共轭系统的高度刚性和平面支架已被广泛认为是 β-淀粉样蛋白 (Aβ) 结合配体必不可少的。在这项研究中，合成并评估了具有不同类型的更灵活的接头作为 Aβ 配体的二苯氧基化合物库。它们中的大多数对 Aβ 1-42聚集体显示出良好的亲和力 ( K i < 100 nM) ，一些配体甚至显示出K i值小于 10nM。构效关系分析表明，接头或取代基的修饰具有很大的灵活性，这挑战了长期以来认为刚性和平面结构专用于 Aβ 结合的观点。三种配体被碘125标记，它们在体外和体内表现出良好的特性，进一步支持这种柔性支架在Aβ成像剂的开发中具有潜力和前景。